USA Financial Formulas Takes $1.45 Million Position in Illumina, Inc. (NASDAQ:ILMN)

USA Financial Formulas acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 10,833 shares of the life sciences company’s stock, valued at approximately $1,448,000. Illumina comprises about 0.2% of USA Financial Formulas’ investment portfolio, making the stock its 17th biggest holding.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Versant Capital Management Inc boosted its position in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares during the period. TD Private Client Wealth LLC raised its position in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after buying an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its stake in shares of Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after acquiring an additional 168 shares during the period. Itau Unibanco Holding S.A. bought a new position in shares of Illumina in the second quarter valued at approximately $61,000. Finally, Private Trust Co. NA increased its stake in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after acquiring an additional 212 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 0.2 %

Shares of Illumina stock opened at $136.19 on Thursday. The firm has a 50 day simple moving average of $140.55 and a 200 day simple moving average of $133.10. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter last year, the business earned $0.33 earnings per share. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. On average, analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ILMN shares. UBS Group boosted their price objective on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and cut their price target for the company from $190.00 to $165.00 in a report on Wednesday, December 11th. Robert W. Baird lifted their price objective on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Canaccord Genuity Group increased their target price on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. Finally, TD Cowen lifted their price target on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $165.63.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.